Five of the six patients with HER2+ breast cancer showing stable disease or an unconfirmed partial response had documented progression with the most recent prior regimen, which contained trastuzumab, and the sixth patient received trastuzumab as part of the second most recent treatment regimen. This evidence concerns the gene ERBB2 and breast cancer.